Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 clients • 8 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
MH2 Technology Law Grp handles Biotechnology & Pharmaceuticals applications, with 243 career applications and 8 pending office actions. Its resolved allowance rate is 87.68%, indicating favorable results across most resolved matters.
Applications reaching allowance averaged 4.17 office actions. The data suggests that successful prosecution commonly involved repeated examination rounds, while the application history provides a focused record for evaluating work in this technology area.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 2 (22%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 2 | 62.3% | +32.8% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
| SMITH, JENNIFER A | 1 | 60.9% | +26.9% |
| LOVE, TREVOR M | 1 | 43.1% | +26.8% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | HOWARD, ZACHARY C | 5d overdue |
| 18681308 | USE OF AN ACID WHEY TO STIMULATE THE GERMINATION OF A PLANT POLLEN GRAIN | ALLEY, GENEVIEVE S | 4d overdue |
| 18044169 | OXIDATIVE METHOD FOR PREPARING A FERTILIZING COMPOSITION | SMITH, JENNIFER A | 33d |
| 18294636 | ANTIBODY-DRUG CONJUGATES | HERNANDEZ, JACKSON J | — |
| 18268450 | MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 17802274 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CANELLA, KAREN A | 53d overdue |
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | HOWARD, ZACHARY C | 5d overdue |
| 18681308 | USE OF AN ACID WHEY TO STIMULATE THE GERMINATION OF A PLANT POLLEN GRAIN | ALLEY, GENEVIEVE S | 4d overdue |
| 18044169 | OXIDATIVE METHOD FOR PREPARING A FERTILIZING COMPOSITION | SMITH, JENNIFER A | 33d |
| 18040468 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | LOVE, TREVOR M | 42d |
| 18294636 | ANTIBODY-DRUG CONJUGATES | HERNANDEZ, JACKSON J | — |
| 18268450 | MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER | VANHORN, ABIGAIL LOUISE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| MCSAF INSIDE ONCOLOGY | 2 |
| Université de Rouen | 1 |
| CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS | 1 |
| Université Paris Cité | 1 |
| AP-HP | 1 |
| ECOLE D'INGENIEURS DE PURPAN | 1 |
| Cosmosoft | 1 |
| Université d'Évry | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1617 | 1 |
| 1627 | 1 |
| 1636 | 1 |
| 1674 | 1 |
| 1731 | 1 |
| 1611 | 1 |
| 1653 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18681308 | USE OF AN ACID WHEY TO STIMULATE THE GERMINATION OF A PLANT POLLEN GRAIN | UNIVERSITE DE ROUEN NORMANDIE | ALLEY, GENEVIEVE S | 1617 | §103§112 | Non-Final OA | 4d overdue | Pending | Feb 05, 2024 |
| 18294636 | ANTIBODY-DRUG CONJUGATES | Centre Hospitalier Regional Universitaire De Tours | HERNANDEZ, JACKSON J | 1627 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18268450 | MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER | UNIVERSITE PARIS CITE | VANHORN, ABIGAIL LOUISE | 1636 | §101§102§103§112 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18333261 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | Mcsaf Inside Oncology | CANELLA, KAREN A | 1643 | §103§112DP | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | Assistance Publique-Hopitaux De Paris | HOWARD, ZACHARY C | 1674 | §102§112 | Final Rejection | 5d overdue | Pending | Apr 24, 2023 |
| 18044169 | OXIDATIVE METHOD FOR PREPARING A FERTILIZING COMPOSITION | Ecole D'Ingenieurs De Purpan | SMITH, JENNIFER A | 1731 | §102§103 | Non-Final OA | 33d | Pending | Mar 06, 2023 |
| 18040468 | HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE | Cosmosoft | LOVE, TREVOR M | 1611 | §103 | Final Rejection | 42d | Pending | Feb 03, 2023 |
| 17802274 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | Mcsaf Inside Oncology | CANELLA, KAREN A | 1643 | §103DP | Final Rejection | 53d overdue | Pending | Aug 25, 2022 |
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | UNIVERSITE D'EVRY VAL D'ESSONNE | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Final Rejection | 92d overdue | Pending | Jan 07, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial87.7% of resolved applications prosecuted by Mh2 Technology Law Grp were allowed, across 243 applications in USPTO records.
4.17 office actions per allowed application on average.
9 pending office actions as of October 2026, for 8 clients, before 8 examiners in 8 art units.
